Abraxane/Bevacizumab

Summary

The protocol will study the effect of the combination of two drugs-Abraxane and Bevacizumab-on a subject's ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. This study drug combination will be given to subjects who have already been treated for their cancer with other chemotherapy, and now their cancer has become worse or has come back again. Neither one of these study drugs has been approved by the FDA for treatment in these three types of cancer.

Timeline

Start

2010-01

Primary completion

2011-11

Completion

2011-11

Outcome

Outcome not reported

Stopped (Enrollment): “Terminated due to low enrollment”

Drugs

Indications